Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA(1c) in New-Onset Type 1 Diabetes

OBJECTIVE: A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that 1) low-dose ATG/GCSF or 2)...

全面介紹

Na minha lista:
書目詳細資料
發表在:Diabetes Care
Main Authors: Haller, Michael J., Schatz, Desmond A., Skyler, Jay S., Krischer, Jeffrey P., Bundy, Brian N., Miller, Jessica L., Atkinson, Mark A., Becker, Dorothy J., Baidal, David, DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Herold, Kevan C., Marks, Jennifer B., Moran, Antoinette, Rodriguez, Henry, Russell, William, Wilson, Darrell M., Greenbaum, Carla J.
格式: Artigo
語言:Inglês
出版: American Diabetes Association 2018
主題:
Emerging Therapies: Drugs and Regimens
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105329/
https://ncbi.nlm.nih.gov/pubmed/30012675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc18-0494
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍